Endocrine Abstracts

Osteoporosis is a progressive disease characterized by excessive bone loss which is often accompanied by augments in marrow adiposity as a result of estrogen deficiency, metabolic abnormalities or medications. Nuclear receptor estrogen-related receptor alpha (ESRRA) has a demonstrated role in energy homeostasis and fat metabolism. To determine if ESRRA is a potential therapeutic target for regulating fat-bone balance, we generated an adipocyte-specific ESRRA knockout mice (ESR...

Background: HIV is associated with decreased bone mineral density (BMD) and decreased muscle mass. Osteoporosis and sarcopenia often co-exist and their onset is multifactorial. Sex steroids play a key role in the homeostasis of bone health and body composition in HIV-uninfected men, but data in MLWH are scanty.Aim: To investigate the frequency of low BMD and sarcopenia and their relationship with gonadal function in MLWH younger than 50.<p class="abs...

Clinical case: A 27-year-old pregnant woman (24 weeks of gestation) was investigated as her Hb level (87 g/l) was low. Laboratory work-up revealed severe, non-PTH dependent hypercalcemia (see Table). This was her first pregnancy, and serum calcium measured once previously 12 years earlier had been normal. The patient had symptoms of increased thirst, constipation and hyperemesis.Diagnostic work up and Treatment: Rehydration and close mon...

Autosomal dominant hypocalcemia type 1 (ADH1), caused by gain-of-function calcium-sensing receptor gene (CASR) variants, is characterized by low parathyroid hormone (PTH) levels, hypocalcemia, hypercalciuria, hyperphosphatemia and hypomagnesemia. Conventional therapy (calcium and active vitamin D) worsens hypercalciuria, which may result in renal complications. Calcilytics, such as encaleret, are negative allosteric modulators of the calcium-sensing receptor (CaSR). T...

Background: Conventional therapy for chronic hypoparathyroidism (cHP) is often unable to maintain stable normal serum calcium (Ca) levels for a full 24 h, to control symptoms, to prevent the detrimental long-term effects on the kidney and to preserve normal bone architecture. Eneboparatide (AZP-3601) is a novel 36-amino-acid peptide specifically designed to activate the R0 conformation of the PTH receptor 1, that results in a prolonged calcemic response and a sustai...

Background: Conventional therapy with oral calcium (Ca) and active vitamin D (vitD) supplementation for chronic hypoparathyroidism (cHP) can induce or aggravate hypercalciuria and may lead to detrimental long-term renal complications. Eneboparatide (AZP-3601) is a novel 36-amino-acid peptide with a short half-life designed to activate the R0 conformation of the PTH 1 receptor which produces a prolonged calcemic response. This phase 2a study examined the effects of e...